Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-11-30 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于控股股东部分股权解除质押和质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the partial release and new pledge of shares by its controlling shareholder. It details the number of shares involved, dates of pledge and release, and the purpose and risks associated with the pledge. The content focuses on share pledging activities by a major shareholder, which is a capital structure update rather than a financial report, management change, or voting result. The document length is short (1031 characters) and it is a direct announcement of share pledge transactions. Therefore, it fits best under the category of Transaction in Own Shares (POS).
2017-11-30 Chinese
关于下属企业天津协智医院管理有限公司完成清算注销的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of liquidation and deregistration of a subsidiary company. It includes details about the liquidation process, official approval of deregistration, and an expected financial impact on the parent company's consolidated profit. The document is short (585 characters) and serves as an official notice rather than a detailed financial report or audit. It does not contain financial statements or detailed financial analysis. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate actions that do not fit other specific categories like Annual Report, Audit Report, or Capital Update.
2017-11-29 Chinese
独立董事关于转让浙江赛尚医药科技有限公司67%股权的独立意见
Board/Management Information Classification · 85% confidence The document is an independent opinion from the independent directors regarding the transfer of 67% equity of Zhejiang Saishang Pharmaceutical Technology Co., Ltd. It references board meeting decisions and compliance with governance rules. The content is a formal opinion on a specific transaction, not a full report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a regulatory filing or certification. It is related to board/management information about a significant transaction and the independent directors' stance on it.
2017-11-24 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of 67% equity in Zhejiang Saishang Pharmaceutical Technology Co., Ltd. by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the transaction overview, parties involved, financial data, terms of the equity transfer agreement, and the impact on the company. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a detailed disclosure of a capital transaction involving equity transfer. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2017-11-24 Chinese
重大资产重组进展暨继续停牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring and the continuation of a trading suspension (stock halt). It details the parties involved, the nature of the transaction (issuing shares to purchase assets and raise funds), and the ongoing due diligence and approval process. The document does not contain financial statements or detailed financial data but serves as an update on the status of a significant corporate transaction and the reason for continued suspension of trading. It is not a full report, audit, or financial statement but an announcement related to a capital restructuring event. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length is short (1565 characters), and it is not merely announcing the publication of a report but providing substantive update information on the capital restructuring progress.
2017-11-08 Chinese
关于签署重大资产重组框架协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a framework agreement for a major asset restructuring involving the purchase of 100% equity of a company. It details the parties involved, the basic terms of the agreement, and the potential impact and risks. The document is relatively short (3009 characters) and focuses on the announcement of a transaction framework rather than providing full financial statements or detailed financial analysis. It is not a full annual or interim report, nor an earnings release or audit report. It is clearly about a significant corporate transaction, specifically a major asset reorganization. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings.
2017-11-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.